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INTRODUCTION 
Within the past three to four years perhaps no other surgical endeavor 
has attracted more renewed attention, both from the lay and medical 
communities, than that of transplantation of solid organs, To discover the 
single most important cause for this sudden burst of interest one need look 
no further than the introduction of the new immunosuppressant, cyclosporine, 
This claim in no way denies that many other important advances have been 
made in the field over the past 20 to 25 years. Several renal transplant 
centers were already obtaining outstanding graft and patient survival rates 
well before cyc1osporine came along 102 , No doubt judicious use of new 
knowledge regarding the value of tissue matching in the Dr histocompatibility 
loci, and the discovery that deliberate blood transfusion protocols in kidney 
recipients could enhance graft survival, as well as careful management and 
selection of recipients all contributed to improvements in results. The 
assertion over t.he importance of cyclosporine also should do nothing to 
diminish the importance of certain other improvements, both technical and 
conceptual, made in the fields of heart, heart.-Iung, liver and pancreas trans-
plantation where several groups had continued to struggle for the kind of 
advances without which cyclosporine would have had a lesser impact3,4,5, 
The importance of the arrival on the scene of anew, more effective 
immunosuppressive agent cannot be properly interpreted without an 
understanding of the larger history of the field of transplantation. This will 
become particularly evident in the early part of this chapter on hepatic 
transplantation. That cyclosporine is far from a "magic bullet" for the 
1 
prevention of rejection will also become evident as we discuss the various 
difficulties and short-comings encountered with its use. 
The recent literature is replete with articles about liver transplantation, 
many of which can serve as comprehensive reviews of the subject 6-9. In 
addition, virtually every major textbook of surgery or transplantation written 
within the past ten years contains a chapter or section concerning hepatic 
transplantation. The major purpose of the present chapter, then, is to serve 
not just as a general review of the subject, but also to share with the 
interested reader some of the issues currently facing those physicians who 
are actively involved in offering liver transplantation as an effective approach 
to the treatment of a large variety of disorders of the liver. 
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COSTS AND BENEFITS OF THERAPY 
Assessing the various costs involved in providing a form of therapy can 
be a formidable job. Furthermore, any form of therapy with which those costs 
run high naturally raises concern over whether the benefits accrued justify 
the costs. On the other hand, these questions are seldom posed by and they 
are difficult issues to address for those physicians who may have devoted a 
life time toward developing and refining the particular therapeutic modality 
under scrutiny. Until recently, transplantation of the liver was such a rarely 
performed procedure, being done in the United States on a continuous basis 
at only one center and at an average rate of less than 20 cases annually, that 
these issues seldom attracted much attention outside the relatively small 
brotherhood of health care personnel intimately involved with these 
procedures. But the improvement in results attending the introduction of 
cyclosporine in late 1979 and early 1980, as will be further emphasized 
throughout this chapter, stimulated such a renewal of interest in the 
procedure that major medical centers throughout the country, prodded by the 
professional and lay communities alike, began to look into the various cost-
benefit ratios of providing liver transplantation as a service. 
By the time the first symptoms of t.he national liver transplant fever 
had become undeniable in late 1982, the key question repetitively raising its 
head was "who pays?" Although several major health insurance companies had 
decided in favor of covering the steep costs of the procedures for their 
policy holders, a far greater number denied any such obligations by 
maintaining that the procedure was still experimental in nature. The various 
state welfare agencies were equally disparate in answering the question of 
payment. 
In an effort to address some of these issues as well as others, the 
National Institutes of Health convened a consensus conference in Washington, 
D.C. during June of 1983. The various opinions, facts and data presented by 
the wide ranging group of specialists invited to speak at the conference as 
well as a consensus statement have been published.10 When interpreting some 
of this information, one must keep in mind both the speculative as well as the 
ephemeral quality of its accuracy. Nevertheless, the most important single 
conclusion of the conference was quite simply that liver transplantation is a 
viable therapeutic modality for a variety of disorders. Although one express 
intention of the conference was to steer clear of any opinions about who 
should pay, or for that matter how much should be paid or to how many or 
which centers, the official statement quite clearly removes t.he label 
"experimental" from hepatic transplantation therapy. 
Formal debate of the question of payment. is beyond t.he scope of this 
chapter. No doubt in the years to come, as liver transplant services begin to 
sprout in medical centers around the world, the issues involved will become 
more popular topics for discussion in a wide variety of venues (Figure 1). 
Accurate information is available, however, regarding some of the costs 
involved with the procedure. These are illustrated in Table 1 for 31 adult 
patients selected at random from 1984 and for the total 55 pediatric patients 
transplanted during the 1983-84 fiscal year in Pittsburgh. The mean costs for 
all patients have a tremendous standard deviation because of the wide range 
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of costs. The median figures give a more realistic accounting of "average" 
costs. Costs were lower for children overall than for adults. The median cost 
for all patients ($75,691) is virtually identical to the median costs for all 
children ($75,927) and for all adults ($75,691). The lowest costs were for 
pediatric patients who only required one graft, and highest for those 11 chil-
dren who needed two or more livers. 
One must keep in mind that these figures are being generated by a 
surgical service that, though the most experienced in the world, is constantly 
pushing the acceptable limits of patient candidacy for the procedure. If t.he 
number of high risk patients could be minimized either by earlier 
consideration for transplantation or by designation into other tracts of 
therapy, these costs could no doubt be lowered significantly. More will be 
said about the question of candidacy later in this chapter. 
Attempting to compare these costs with alternative methods of care is, in 
most cases, a mute point since no such alternatives exist. In these instances 
one must compare the costs of liver transplantation with the costs of death. 
Although the analysis begins to stretch beyond the intended scope of this 
chapter, a look at the numbers in terms of how many patients survived the 
treatment and how many are restored to a productive life is worth accounting. 
Table 2 shows that in the pre-cyclosporine era, of the 25 patients 
surviving five years or more and still living, 20 are employed full time, 
attending school, or involved in managing households. Although cyclosporine 
therapy has not been available tor more than four years, Table 2 also shows 
similar information about 81 adult patients surviving 6 months or more after 
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transplantation under the new drug. Of the 7 patients in the cyclosporine era 
who are disabled, 4 require recurring hospitalization for continued physical 
rehabilitation and 2 for adjuvant tumor therapy. Virtually all children are 
either back in school or otherwise doing well.ll 
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HISTORICAL PERSPECTIVE 
The transplantation of vascularized, solid organs was a logical extension 
of the development of the techniques for vascular anastomoses. Alexis Carrel 
has been credited with showing that blood vessels could be sewn together 
with a reasonable expectation that blood would continue to flow through them 
for extended periods of time.u Emerich Ullman, in 1902 demonstrated that the 
removal of a kidney from one animal and revascularization in another was a 
technical feasibility.13 Other early experiments revealed that auto transplants 
could be done successfully, but that even by using the same surgical tech-
niques, allotransplants failed. This led Carrel in 1910 to claim that "the 
physiologic disturbance could not be considered as brought about by surgical 
factors. The changes undergone by the organ would be due to the influence 
of the host, that is the biological factors." 14 Thus with these technical 
successes, Carrel also demonstrated an observance, if not an understanding of 
the phenomenon of tissue rejection. No less so with the liver, the early 
history of organ transplantation can be broken down into that dealing with 
advances in surgical methodology and that involving developments in 
immunology . 
.Early Bxperimental Techniques 
The early work with heterotopic liver transplantation in dogs, reported 
first by Welch 15 and subsequently by othersl 6-18 was done without immuno-
suppression. These organs were destroyed after several days, apparently as 
a result of rejection. Nevertheless, the observation that they produced bile, 
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at least for an initial period of time, and appeared normal in color and texture 
was encouraging. 
But the real test for the methodology for removal of a liver from one 
animal and revascularization into another took place when, in the late 1950's, 
Moore 19 at Peter Bent Brigham Hospital and Starzl20, then at Northwestern 
University in Chicago, developed their techniques for orthotopic transplant-
ation in dogs. Survival following orthotopic replacement of an unpaired, vital 
organ requires, by definition, that. a certain high level of organ function be 
obtained. In these early experiments on unmodified canine recipients, the 
death rate was exhorbitantly high. Despite these discouraging results, Starzl 
persisted in his efforts to improve the surgical technique, the methods of 
organ preservation, and the management of anesthesia so that by 1965, he 
could report that 22 Of 23 unmodified dogs survived at least two days 
following surgery, with 19 surviving at least six days. These animals served 
as one of the control groups in a series of elegant experiments which were 
presented in a landmark paper at the OS~b annual meeting of the Society of 
University Surgeons in 1965.21 
These studies demonstrated not only the course and nature of rejection 
of liver grafts in dogs, but also proved that, just as with renal allografts, 
rejection could be modified successfully with immunosuppression. In the same 
paper, Starzl only casually mentions the improvements in techniques respons-
ible for the virtual elimination of perioperative mortality in these animals, an 
accomplishment which he modestly attributes to having gained "considerable 
experience". The paper belies the kind of Herculean effort required from 
Starzl and his colleagues to develop a whole new technology I perhaps the most 
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complex and demanding in the field of surgery, technology that was necessary 
simply in order to get animals to survive long enough to approach the next 
great hurdle, that of tissue rejection. Without belaboring the point further, 
suffice it to say that what Starzl refers to as "gaining considerable 
experience" was responsible for his developing most of the techniques which 
are used today in the clinical transplantation of the liver. This will become 
more evident as we enter the discussion. of operative techniques. 
Early Experimental Immunology 
The early observation that unmodified canine liver recipients would 
eventually succumb to rejection of their livers in a way not dissimilar to that 
seen with renal allografts was less surprising than the observation that 
sometimes the liver grafts failed to obey these so-called normal rules. Starzl 
reported occasional long term survival in unmodified dogs_ in 1961 22. Later, 
Garnier 23 observed even greater acceptance of liver grafts in unmodified 
pigs. These results were in contrast to those seen with random skin or 
kidney grafts, both of which were promptly rejected in all unmodified dogs or 
pigs. In 1969, CaIne went on top show that unmodified pigs who failed to 
reject their liver allografts were subsequently rendered hyporeactive to skin 
or kidney grafts from the same donor2". Although a similar immunosup-
pressive effect of liver grafts were not found in dogs by Starzl21 or in 
primates by Myburgh2S, Zimmermann26 demonstrated an identical phenomenon 
in rats. 
Early theories proposed to explain the apparent "privileged status" of 
liver grafts as well as the immunosuppressive effects in some animals were 
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largely speculative.3 One thought was that since the liver is such a large 
organ, the large antigenic mass simply overwhelmed the immune system of the 
recipient. Another theory was that since the liver itself comprises a large 
part of the reticuloendothelial system, a grafted organ replaced a large part 
of the machinery necessary for the organism to mount an immune response. A 
third proposal held that the transplanted liver released soluble factors into 
the serum which helped to block its own rejection. 
Subsequent work with the rat model by the group at Cambridge has 
resulted in an increased understanding of the possible mechanisms for this 
so-called "privileged status "27. These authors conclude that the fate of liver 
grafts is primarily determined by immune response genes of the recipient. 
Accordingly, so-called high responders reject livers as readily as they do 
other organ grafts whereas low responders not only fail to reject livers, but 
also appear to develop profound systemic tolerance to donor specific antigens. 
They have shown that this specific tolerance is accompanied by deletion of 
specific clones of cells normally responsible for reaction to the specific donor 
antigens, while those clones responsive to other antigens are retained. In 
addition, they found powerful and specific immunosuppressive molecules in the 
sera of liver grafted rats. They have found no evidence for the development 
of populations of either donor specific or non-specific suppressor cells in 
these tolerant rats. 
The direct impact of these studies upon clinical liver transplantation is 
undetermined. Since, as yet, no similar mechanisms have been delineated in 
humans. On the other hand, working with the canine model, Starzl was 
eventually able to obtain prolonged survival using immunosuppression with 
10 
azathioprine 3,at.aa and anti-lymphocyte serum or its globulin derivative 
(ALG)3.29-32. These early successes using immunosuppressive agents to treat 
rejection of the liver in animals, combined with the massive experience ac-
cumulated with the operative technique led to the first human trials of hepatic 
trans plan tation. 
Barly Clinical Trials 
On March 1, 1963, Starzl performed the first transplantation of the liver 
in a human.33 But that winter day in Denver, Colorado is more important to 
the field as the day on which Starzl finally broke the ice than as the date on 
which liver transplantation became a clinical reality. This first attempt was 
the logical next step in the progression of the intensive research efforts 
started in the Denver and Boston dog laboratories over four years earlier. 
Nevertheless, the first patient, a three year old boy with biliary atresia, died 
of uncontrollable hemorrhage on the operating table. Over the next ten 
months, four more attempts in Denver and one each in Boston and Paris were 
also unsuccessful (Table 3), thus halting further clinical trials for three more 
years. Starzl's sixth attempt in November, 1966 and seventh in May, 1967, also 
failed to provide prolonged survival. The first patient to obtain extended 
survival was a 1 1/2 year old girl transplanted on July 23, 1967 as treatment 
of primary hepatocellular carcinoma. She died thirteen months later of diffuse 
metastases. 
In May, 1968 in the United Kingdom, Caine of the University Hospital at 
Cambridge and Williams of King's College in London embarked upon their series 
which, together with the Denver series of Starzl, account for the overwhelming 
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majority of cases performed in the world during the subsequent decade. 
During that interval, however, single cases or small series of liver transplants 
in humans were also reported from Boston34•35, Los Angeles36, Montrea131, 
Bonn38•at Sao Paulo40, Calgary41, New York City42, Richmond43, Minneapolisu , 
Manchester45, and OSl046. The importance of these early trials and the 
experience that they generated with the use of a variety of regima of 
immunosuppression, originally developed for treatment of kidney recipients 
(Table 4) cannot be over estimated. 
Yet by the end of 1978, little progress had been made toward 
significantly improving survival following hepatic transplantation. The best 
patient survival reported during this decade was a 50% one year rate reported 
by Starzl for his so-called Series II patients, a group of 30 patients 
transplanted between 1976 and 1978. However, the subsequent 26 patients 
were the subject of a paper entitled "Decline in Survival Following Liver 
Transplantation" and published in 1980 4'. Of these 26 cases, only six (23%) 
survived beyond the first year following transplantation (Figure 2). Of 
particular note, most of the techniques of the operative procedure, of 
anesthesia management and postoperative care as well as those of organ 
preservation had been developed to a point where rejection or over 
immunosuppression in an attempt to control it were the major causes of death 
in a majority of patients during that era. Clearly the field lay open and 
fertile for the introduction of anew, more potent and hopefully more specific 
immunosuppressant. 
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The Beginning of the Cyc1osporine Bra 
An editorial in the July 11, 1981 issue of the British Medical Journal 
declared: "Liver transplantation has come of age: It gives a chance of 
excellent rehabilitation for patients with no other treatment available and the 
operation is probably less costly than prolonged care of a patient dying of 
liver disease in the hospital." The journal was responding to the reports 
from both Denver and Cambridge of marked improvements in survival of liver 
recipients following the introduction of the then new immunosuppressive agent, 
cyc1osporin A.48-S2 In particular, Starzl's initial report of 71% one year 
survival was startling and compared quite notably with previous results 
(Figure 3). 
The ultimate impact upon the whole field of liver transplantation of 
these early reports has been a rebirth of enthusiasm for the procedure of 
epidemic proportions. At the end of 1980, after 17 years of clinical 
transplantation of the liver, the total number of cases performed in the world 
was probably less than 350. Most of these had been done at two centers 
(Denver and Cambridge), with steadily increasing involvement by two other in-
stitutions (Hanoverl13 and Gronigen54 ). In four years following the 
introduction of cyclosporine, the world total will soon exceed 800 cases and 
the number of centers around the world planning active involvement in the 
field is expanding on a weekly basis. Figure 4 shows the location of 
institutions participating at the mid-point of 1984, along with the number of 
cases at each center up to that time. The annual rate of cases in Pittsburgh 
has swollen step-wise from 30 in 1981 to over 175 in 1984. The coming years 
will no doubt witness the emergence of other centers able to take an active 
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· role and share the burden of providing liver transplantation to the increasing 
population of potential recipients. 
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THE LIVER DONOR 
Several surveys have revealed that approximately 1 to 1.5% of all in-
hospital deaths that occur annually in the United States are the result of 
irreversible brain damage.S5-sa Thus the potential pool of donors has been 
estimated to be between 10,000 and 20,000 annually. Yet fewer than 3,000 
donors per year provide organs for transplantation. The criteria which define 
a satisfactory kidney donor have become fairly standardized.59 For the most 
part, many of these kidney donors would also be satisfactory donors for livers 
as well as hearts, pancreases and other extrarenal organs. Yet probably 
fewer than 25% of kidney donors are actually utilized as extra-renal organ 
donors. The reasons for this under utilization of organ donors has been re-
lated largely to the lack of knowledge in both the medical and non-medical 
communities about the tremendous increase in demand for extra-renal organs 
following the improvement in results with these transplants which attended the 
introduction of cyclosporine. The demand for donor livers at the end of 1984 
remained concentrated in only a few centers across the country, with the 
University of Pittsburgh program continuing to utilize the vast majority of a-
vailable organs. The high volume of liver transplant operations performed at 
Pittsburgh has been dependent upon the referral of donors to Pittsburgh by 
a large number of other medical centers all across the country, most of which 
are not involved, as yet, in liver transplantation. But, as more medical 
centers enter the arena of liver transplantation, increasing the local availa-
bility of donor organs will become critical to meeting the needs of these 
transplant programs. This, in turn, will require continuing efforts on the 
part of transplant programs at making both the public and the rest of t.he 
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medical community more aware of these needs so that fewer donor organs are 
wasted. 
The techniques for procurement of multiple organs from a single donor 
have been described in many previous publications.6CHI4 These methods have 
been designed to minimize or eliminate damage done to the various organs by 
warm ischemia. The basic principals of liver procurement are outlined herein. 
More detailed descriptions are available elsewhere.60-64 
Donor Maintenance 
Organ donors are heart beating cadavers. Prior to the declaration of 
death, the care of a brain injured patient is the sole responsibility of the 
patient's primary physician(s) and should not be altered in any way which 
might be detrimental to the patient just because that patient is viewed as a 
possible organ donor. On the contrary, the functional quality of transplanted 
donor organs depends, to some degree, on how successful the primary 
physician(s) has (have) been in maintaining the normal physiology of the 
patient. Once a patient has been declared dead as the result of the complete 
and irreversible cessation of all brain function and permission for organ 
donation has been granted by the appropriate next of kin, then usually, the 
care of that cadaver is turned over to the transplant organ procurement 
agency. 
At this point, the task of the procurement officer in charge of the 
donor is to assess the overall status of the donor in terms of its state of 
hydration, its cardiodynamic stability and ultimately, the level of end organ 
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function. Any overt abnormalities are corrected and an attempt is made to 
maintain a steady urine output of 2 mls./ kg. per hour or more. Diabetes 
insipidus, if present, is treated with judicious use of vasopressin and fluid 
losses are replaced with a solution of extracellular composition (such as 
lactated Ringers solution). Care must be exercised to avoid over hydration as 
well, especially if consideration is being given to procurement of the heart 
and lungs. A central venous or pulmonary artery catheter is usually required 
for this purpose. 
Hypoxia and hypotension are the two· greatest dangers to the donor 
liver. Yet the liver is unique in its capacity to regenerate following injury. 
How extensive a period of hypoxia or hypotension a liver will tolerate and still 
provide satisfactory function in the recipient following transplantation is 
difficult to determine. A donor with a prolonged history of arterial hypoxia as 
evidenced by serial blood gas determinations warrants careful examination of 
the liver function tests. Likewise, a history of multiple or repeated cardiac 
arrests, of prolonged hypotension requiring the use of high doses of pressor 
agents for longer than brief periods of instability may have caused unaccept-
able degrees of hepatic injury. On the otherhand, low doses of dopamine or 
inotropic agents may prove useful for maintaining good renal function and 
enhancing cardiac output. 
The major point of this discussion is that in making the decision about 
whether to use a particular donor liver, one must take into account a number 
of variables. As an isolated set of values, liver function tests, whether 
entirely normal or grossly abnormal, are not particularly useful. Large 
elevations in serum transaminase levels as the result of a brief period of 
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hypotension or of a recent episode of cardiopulmonary resuscitation often do 
not indicate an hepatic injury significant enough to preclude transplantation 
of the organ. On the other hand, a donor with extensive hepatic necrosis and 
in which massive fluid shifts have occurred may exhibit grossly normal serum 
transaminase levels. Serum bilirubin may be elevated secondary to the trans-
fusion of blood, although usually with a higher than normal indirect fraction. 
A prolonged prothrombin or partial thromboplastin time should alert one to the 
possibility of the development in the donor of disseminated intravascular 
coagulation (DIe). Donor DIC may develop as the result of massive brain or 
other tissue necrosis secondary to multiple· trauma or may indicate overt 
sepsis. In either case, an uncorrectible or unexplained coagulopathy should 
be considered a relative contraindication to liver donation, particularly if 
other evidence points to the presence of a significant hepatic injury. 
Ultimately, responsibility for the decision about whether to use a 
particular liver for transplantation is borne by the surgeon performing the 
transplant. In making that decision, the surgeon may also take into account 
the condition of the recipient as well as the size, age and blood type of the 
donor in terms of the relative frequency with which such a donor becomes 
available. For example, small pediatric donors are quite rare and the number 
of waiting candidates large. The number of such patients which die waiting 
for the appropriate sized donor is still greater than the number that get 
transplanted. Hence, when they become available, these donors are only 
infrequently deemed to be unsatisfactory. 
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Tecbnique of Donor Hepatectomy 
The heart beating cadaver is placed on the operating table in a supine 
position. A heating blanket placed under the body is useful in maintaining 
donor core temperature above 340 C and thus avoiding premature development 
of cardiac arrythmias. An experienced anesthesiologist is invaluable in 
maintaining the integrity of donor cardiodynamic and pulmonary stability. An 
arterial catheter and a central venous or pulmonary artery catheter often 
have proven useful for the intraoperative management of the donor. 
The donor abdomen is opened through a long midline incision combined 
with midline sternotomy. This provides excellent exposure to the abdominal 
viscera and allows for the option of removing the heart and/or lungs as well. 
In general, the liver procurement team performs the dissection of the hepatic 
hilum first. The hepatic arterial supply is identified and traced back to its 
origin from the aorta. The common bile duct is divided as close to the 
duodenum as possible, thus providing maximum length for anastomosis in the 
recipient. An incision is made in the gallbladder and bile flushed from the 
biliary tree with a bulb syringe. The portal vein is cleaned and the 
confluence of the splenic and superior mesenteric veins isolated. The latter is 
facilitated by dividing the pancreas between mass ligatures. A cannula for in-
fusion of cold fluid is insert-ed into the portal vein via the splenic or 
mesenteric vein. 
Once the hepatic hilar dissection has been completed, the nephrectomy 
team proceeds with isolation of the kidneys. The authors prefer in situ flush 
of the organs. Large bore cannulas are inserted into the distal aorta and 
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inferior vena cava at the level of the iliacs, the former for infusion of cold 
preservation solution into the arterial tree and the latter for drainage of 
blood and fluid from the venous system. 
The so-called precooling step can be started at any time after the 
hepatic hilar dissection has been completed. The cannula in the distal vena 
cava is useful for draining off central venous volume as cold (4-1oo C) lactated 
Ringers solution is infused through the liver via the portal vein cannula. 
This is important to avoid central venous hypertension which may cause 
swelling of the liver. The precooling step serves to cool the liver while it is 
still being perfused with oxygenated blood via the hepatic artery. In this 
way, warm ischemia is virtually eliminated. Infusion of cold lactated Ringers 
is continued until donor core temperature falls to 28-3oo C or until cardiac 
arrythmias develop. In practice, a stable donor will accept 3 to 5 liters of 
portal infusion over approximately 45-60 minutes, with an attendant release 
via the vena caval cannula of 2 to 4 liters. 
The in situ flush of the aorta with preservation fluid (Collins or another 
fluid of intracellular composition) is started as soon as pre-cooling is thought 
to be complete or at any time that cardiodynamic instability causes arterial 
perfusion pressures to become unsatisfactory. The aorta is clamped at the 
diaphragm, above the celiac axis, and the flush begun via the cannula in the 
distal aorta. At the same time, the vena caval cannula is opened and the fluid 
infusing through the portal vein is changed from lactated Ringers to 
preservation solution for an additional liter of flush. The aorta is re-clamped 
below the celiac axis after about 200-500 mls. have been infused through the 
artery. While the kidneys continue to be flushed, the aorta is divided 
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between the celiac axis and renal arteries and the liver is removed. The 
supra-hepatic vena cava is divided at the base of the atrium and a small cuff 
of diaphragm left on the specimen. The hepatic ligaments are rapidly divided, 
the infra-hepatic vena cava divided just above the renal vein and the liver 
lifted out of the abdomen. The organ is placed in plastic bags, packed in an 
ice slush solution and transported to the recipient hospital. 
Liver Preservation 
The average time interval at Pittsburgh between devascularization of a 
liver in the donor and revascularization in the recipient is 4 1/2 hours with a 
range of from 60 minutes in locally procured organs to over 12 hours in those 
flown in from the west coast. In general, an effort is made to limit the cold 
ischemia time to less than 6 to 8 hours. This usually means starting the 
recipient procedure approximately two to three hours before the arrival of the 
donor organ at the recipient operating room. The timing is varied according 
to the anticipated degree of difficulty of the recipient hepatectomy. 
Much research is currently being devoted to improving the methods of 
hepatic preservation. These efforts have centered around three main areas. 
One involves attempts at cytoprotection and is founded on the principal 
that the major injury to the liver caused by hypotension or hypoxia in the 
donor or by the period of cold ischemia can be minimized by treatment of the 
liver or the donor with so-called cytoprotective agents. Different authors 
have proposed the use of calcium channel blockers85-6." somatostatin88, 
coenzyme Q89-71 and various prostaglandins.12-75 
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Protection may also be afforded to cells by a new method of cold 
storage called vitrification. This technique is being studied by the MRC 
Medical Cryobiology Group in Cambridge:16 It involves very slow cooling of 
tissue under conditions of high atmospheric pressure with the intent being to 
avoid crystallization of tissue water while at the same time lowering tissue 
temperatures well below the freezing level, thus effectively arresting tissue 
metabolism. 
A second area involves developing various methods of perfusion of the 
liVer. Cold perfusion of the liver has been attempted by several authors.".".,8 
The extensive experiments of Brettschneider, et a1 showed that these methods 
of cold perfusion, even if combined with oxygenation of the perfusate, allowed 
no significant prolongation of preservation times beyond those allowed by 
simple cold storage. The extensive experience with cold perfusion for 
preservation of the kidney has demonstrated that these methods yield no clear 
advantage over simple cold storage, as witnessed by the general lack of 
agreement among kidney transplant centers over which is the preferred tech-
nique."e,ao The situation might change, however, if cold perfusion were to 
prove to be the preferred method for continual delivery of a cytoprotective 
agent. 
The use of a warm, oxygenated perfusate may eventually prove a 
superior method for preservation of the liver. Rather than cool the liver in 
order to minimize its metabolic demands during a period of requisite ischemia, 
perhaps a better approach would involve eliminating the ischemic period 
altogether and providing the liver with everything that it needs during the 
time interval that it is between donor and recipient. Removal of the liver and 
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placement of the organ into an extracorporeal circuit which employs a blood 
pump, oxygenator, and heat exchanger is combined with the administration into 
the circuit of appropriate metabolic substrate (glucose and amino acids) and 
the occasional use of a dialysis membrane. An even simpler solution may 
involve removal of the various organs to be preserved en bloc with placement 
into a preservation box. Such a circuit might include the heart and lungs, 
liver, small bowel, pancreas, and kidneys. Critical to these techniques will be 
minimizing blood loss from leaks and hemolysis, avoiding thrombosis or the 
development of coagulopathies, and eliminating contamination with bacteria, 
fungi or other infectious agents which could lead to sepsis in the recipient. 
At the present time, the only method of assessing the quality of a liver 
graft after it has been procured is to revascularize it in the recipient and 
then wait to see if it provides function adequate to support life. As will be 
discussed later in this chapter, although inadequate function of a grafted 
liver is the least common of the three major reasons for retransplantation, it 
is nevertheless the most devastating. Eliminating primary non-function as a 
cause of failure of a liver graft would result in decreasing the overall 
retransplantation rate by 25%.81 Clearly, one can begin to understand the 
importance of developing ex vivo methods for measuring the degree of damage 
sustained by a liver either in the donor, at the time of procurement or during 
the subsequent period of cold storage. Histological examination by either light 
or electron microscopic techniques have been inadequate for this purpose. 
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THE LIVER RECIPIENT 
Indications for Liver Transplantation 
The list of diseases leading to liver failure which can be corrected by 
hepatic transplantation reads like a textbook of hepatology. Table 5 shows the 
major diagnoses of 244 patients transplanted under cyclosporine therapy from 
March 1, 1980 to June 30, 1984, a period of time which will allow for a minimum' 
followup (at the time of this writing) of six months. The most frequent 
indication for liver replacement in adults is post necrotic cirrhosis, usually 
following chronic active hepatitis. In children, if one includes with biliary 
atresia other congenital disorders of intrahepatic bile ductule formation, one 
can account for over 60% of patients 18 years old or younger who undergo 
liver transplantation. 
A comparison of the indications for transplantation before and after the 
introduction of cyclosporine therapy reveals some important differences. 
Among adults, alcoholic cirrhosis and hepatic malignancies have become less 
frequent indications for liver replacement while the diagnoses of primary 
biliary cirrhosis and sclerosing cholangitis have become much more common. 
The list of metabolic disorders for which liver transplantation is indicated also 
has become more diverse. The reasons for these changes will become more 
evident later in this chapter, but in general, the survival rate following liver 
transplantation now exceeds that for other forms of therapy for virtually all 
causes of liver failure and this has had a major impact upon the selection of 
recipients. 
Figure 5 shows actuarial survival curves for adults and children. The 
actuarial survival rate for all patients combined is 68% at one year and 
remains at 60% after the third year. Children have a 76% one year and a 74% 
five year survival rate, compared to 62% and 50% for adults at the same 
milestones, respectively. 
post necrotic cirrhosis 
Most of these patients have so-called non A, non B hepatitis of a 
chronic nature and have developed cirrhosis with all of its sequelae. The 
actuarial one year survival rate in the overall group of patients in this 
category is 62% (see Figure 6). The best results have been obtained in 
patients in whom nutritional depletion or prior immune depression with steroid 
therapy has not taken place. The one year survival rate in 45 of these 
patients who are aged 39 or less is 66.5% (Figure 7). Only five of 11 patients 
over 40 years of age survived the first year. Three of these patients are 
alive at 6, 9 and 12 months. Three others lived beyond one year, but all later 
died within 2 1/2 years of transplantation. On the other hand, in patients 
with disabling complications of cirrhosis, delaying transplantation in an at-
tempt to temporize with other forms of therapy may seriously hinder long term 
survival. 
Five patients transplanted under cyclosporine therapy had positive sera 
tests for hepatitis B surface antigen and for E antigen. All were treated with 
various regima of human anti- hepatitis B immune globulin and attempts have 
been made to actively immunize all patients transplanted since vaccine (Hepta-
vax-B, Merck, Sharp &. Dohme) has become available. One patient became 
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antibody positive and antigen negative for over 6 months. A second patient 
became antigen negative for a brief period following surgery. All patients 
eventually reverted to their original hepatitis serology (positive for surface 
antigen and negative for antibody). Three of these patients died at 5, 14 and 
14 1/2 months after transplantation. One of these three died with entirely 
normal liver function. The other two patients died of septic complications 
attending the development of recurrent liver failure, both with 
histopathological evidence of recurrent hepatitis. The other two patients are 
presently alive 1 and 3 years atter transplantation. The latter patient, 
although remaining antigen negative for over six months, eventually became 
antigen positive and has recently recovered from an episode of acute hepa-
titis. This limited experience suggests that hepatitis B positive patients 
remain at high risk for developing recurrent disease in the transplanted 
organ. Further attempts to transplant these patients must be accompanied by 
renewed efforts at eradicating the virus and preventing recurrent infection. 
Because of the lack of serum markers for non A, non B hepatitis, the 
incidence of recurrent disease among patients transplanted for this entity is 
not known. Only two of these patients developed episodes of what appears to 
have been acute hepatitis and both have recovered fully. Overall, the results 
in these patients are quite good and they remain a group for which trans-
plantation should be considered early. 
primary biliary cirrhosis 
Virtually all of these patients are women in their fifth or sixth decade 
who have had documented disease for ten to twenty years or more. Many are 
26 
deeply jaundiced with bilirubin levels in the 20 to 30 mg./dl. range and have 
ascites, portal hypertension, and severe bone disease. Recurrent bleeding 
from esophageal varices, repeated episodes of encephalopathy, or a sudden 
and relentless rise in bilirubin above 10 mg./dl. are the most frequent reasons 
for referring these patients for transplantation. Although liver replacement 
can be a relatively easy operative procedure in many of these patients, 
advanced age, advanced liver disease or a history of previous abdominal 
surgery are all factors which not only can markedly increase the operative 
risks, but also may complicate recovery following transplantation. 
The actuarial survival rate in these patients is 69.4% at one and five 
years (Figure 6). Because of severe, pre-existing osteoporosis, complicated by 
immunosuppressive therapy, 10 of these 36 patients developed vertebral body 
compression fractures of a severity which required them to be hospitalized in 
rehabilitation centers following discharge from the hospital. 
The question of recurrence of PBC in the transplanted liver has been 
raised before.82 In virtually all of these patients, the anti-mitochondrial 
antibody titers remain positive following transplantation. In addition, the 
histological appearance of chronic rejection of an hepatic allograft is extremely 
difficult to distinguish from primary biliary cirrhosis. The authors have seen 
chronic rejection in this group of patients, but do not believe they have seen 
recurrent PBC. 
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sclerosing cholangitis 
Until recently, patients with sclerosing cholangitis (SO) had not obtained 
survival rates following liver transplantation as high as those for other 
diseases. The major reason for this has been the fact that the vast majority 
of these patients have had multiple operative procedures designed to treat 
extra-hepatic bile duct obstruction. The presence of extensive, dense adhes-
ions in the face of portal hypertension can lead to inordinate blood loss 
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during the transplant operation~ Furthermore, pre-existing infection in 
obstructed bile ducts greatly increases the- risk of developing sepsis following 
surgery. Finally t in the past, because of the temptation for surgeons to treat 
the disease with repeated sundry procedures, many of these patients were re-
ferred for transplantation long after becoming moribund from advanced hepatic 
failure. 
A recent analysis of survival statistics reveals that 13 of the overall 
group of 21 (62%) SC patients transplanted in Pittsburgh are still alive from 6 
to 36 months following transplantation, with only one death occurring after six 
months. (The actuarial survival curve is shown in Figure 6.) 
In making the diagnosis of sclerosing cholangitis, one must be wary of 
the possibility that the patient has a duct cell tumor. The absence of a 
history of ulcerative colitis or initial presentation of the disease in an older 
patient should increase the suspicion that malignancy may be the primary 
diagnosis. In addition, some evidence suggests that a long history of SO may 
predispose to development of duct cell tumor. 
The treatment of colitis in these patients requires careful individual-
ization. Those patients with a significant risk for developing colonic 
malignancy by virtue of having a long history (greater than 10 years) of 
active colitis are theoretically at even greater risk when under 
immunosuppression therapy following transplantation. Whenever possible, if 
liver transplantation is a consideration for a patient, total proctocolectomy 
should be delayed until after the transplant. The presence of intra-abdominal 
adhesions and/or an ileostomy significantly increase the operative risk and 
may complicate recovery. If colitis is active following liver transplantation, 
definitive surgical therapy should be contemplated three to six months later 
when recovery is complete. The risk for recurrence of SC in the transplanted 
liver in patients with or without active colitis is not known, but no such cases 
have been reported thus far. 
malignancies 
When discussing the results of liver transplantation for malignancies, 
one needs to distinguish between primary and metastatic lesions and between 
incidental and diffuse primary lesions. The initial determination must be that 
tumor is confined strictly to the liver and the assumption, therefore, is that a 
cure can be affected by total hepatectomy. 
Until recently, the only reports involving metastatic lesion came from 
CaIne at Cambridge. All five of their patients died from recurrent tumor 
within one year of transplantation and their conclusion has been that 
metastatic malignancy should not be an indication for transplantation of the 
liver.53 On the other hand, Huber, Margreiter and their associates from 
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Innsbruck, Basel and Seattle reported the successful treatment of a 43 year 
old woman with hepatic metastases from breast carcinoma by liver replacement 
combined with toxic doses of cyclophosphamide and irradiation followed by 
reconstitution with stored autologous bone marrow.84 The patient is alive and 
free of tumor over two years later (persoDal co •• UDicatioD). This novel 
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approach, though still experimental, nevertheless belies exciting possibilities 
for the future. 
Primary hepatocellular tumors are found in association with diseases that 
also cause cirrhosis and liver failure. In the combined Denver and Pittsburgh 
series under cyclosporine immunosuppression, three patients with chronic 
active hepatitis, four with hereditary tyrosinemia, one with alpha-l-antitrypsin 
deficiency and one with sea blue histiocyte syndrome had such associated 
hepatomas. In all but one of these patients, the existence of the tumor was 
either known or strongly suspected prior to the transplant operation. In all 
of these cases, resection was not an alternative because of the presence of 
hepatic failure or extensive cirrhosis from other causes. A resection had been 
attempted in one patient with hereditary tyrosinemia with subsequent 
development of deep hepatic failure being the cause for referral of the patient 
for transplantation. Among the nine patients who survived, with follow up of 
from ten months to 3 1/2 years, (eight of whom are still alive), none have 
developed recurrent tumor. 
Primary hepatic malignancies with diffuse involvement of the liver have 
been the major cause for liver t.ransplantation in a total of 32 patients, 
(exclusive of those with cirrhosis or hereditary tyrosinemia), treated with 
transplantation from March, 1963 to September, 1983. Table 6 lists the tumor 
types for both groups of patients. 
Twenty of these patients were treated before the introduction of cyclo-
sporine, twelve of whom survived long enough to observe them for evidence of 
recurrent tumor. Seven of these patients died between 2 and 11 months, four 
more between 13 and 54 months following transplantation. Metastatic disease 
was present in all 11 and was a major factor in the death of 7 of these 
patients. One patient transplanted for a sarcoma of undetermined cell type, 
and who had miliary abdominal metastases at the time of transplantation, is 
alive 8 years after later with no evidence of active growth of residual tumor. 
An actuarial survival curve is shown in Figure 6 for the twelve patients 
with tumors treated in the cyclosporine era. Eight survived at least one year 
and five are still alive between 1 1/2 and 3 1/2 years postoperatively. Two of 
the five long term survivors have known metastatic disease, one of whom has 
had a positive response to chemotherapy. 
The fibrolamellar type hepatoma has been described as a particularly 
slow growing variant of hepatoma.85•86 Our experience suggests that these 
tumors represent a group of patients for whom transplantation may offer both 
reliable palliation and a reasonable chance for cure. This variant was origin-
ally described in 1956 by Edmondson87 , and further elucidated by Peters in 
1975 88. Five patients in the cyclosporineera have been identified as 
having this type of tumor. Three patients are alive and tumor free, one over 
three years, the other two over one year after transplantation. One of the 
remaining two died after 2 1/2 years and the other is alive after 31 months, 
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having undergone chemot.herapy for t.reatment of pulmonary metastases. This 
patient is remarkable for having originally undergone a right trisegmentectomy 
for her tumor in 1977, with transplantation having been undertaken 4 1/2 
years later for recurrence of tumor in the residual liver. 
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Three patients in the cyclosporine group had epithelioid heman-
gioendothelial sarcomas. Two died, one of sepsis at 79 days, the other of 
metastatic disease aft.er 16 months. A total of seven patients had 
cholangiocarcinomas, five of which were Klatskin's tumors. All three Klatskin's 
tumor patients from the pre-cyclosporine era died, one at two months with no 
evidence of metastatic tumor and two of metastatic disease at 24 and 54 
months. One of two patients with KIat.skin's tumors treated under cyclosporine 
survived the perioperative period, eventually succumbing to metastatic disease 
after 8 1/2 months. The two other patients with non-Klatskin's 
cholangiocarcinomas died at 12 and 20 months of metastatic tumor. 
This experience is similar to that reported from other centers. CaIne 
reported 24 patients with primary hepatoma, 20 of whom did not have cirrhosis 
and therefore, presumably had t.umors which were unresectable by virtue of 
their extensive involvement of the liver.s3 Five of these patients obtained 
survival for two years or more, two of whom then died of disseminated tumor, 
three of whom lived five years or more without evidence of recurrence. Of all 
120 cases in the Cambridge-Kings College series, 26 survived for six months or 
more and although 15 (58%) of these died as the direct result of tumor 
recurrence, CaIne concludes that transplantation improved the quality of life 
in these patients, therefore providing worthwhile palliation. 
Since in our experience, with the exception of about 50% of patients with 
fibrolamellar hepatomas, virtually all hepatic malignancies have recurred, many 
in less than one year and often with such an aggressive behavior that death 
occurred very rapidly after the appearance of the recurrence, further 
attempts to treat tumor patients with malignancies are justifiable only if 
combined with other therapeutic modalities. More experience needs to be 
obtained in t.his arena to determine whether transplantation will become a 
satisfactory form of treatment for tumor patients. 
Budd-Chiari syndrome 
Thrombosis of the hepatic veins has presented as an indication for liver 
transplantation in both the acute and chronic setting. Six of the seven 
patients in the authors' series were treated after the introduction of 
cyclosporine. The one patient from the pre-cyclosporine period and three 
from the current series are still alive at 10 and 4 1/2 years and 54, 9 and 8 
months. One patient died of sepsis in less than one month after transplanta-
tion, but two others obtained long term survival of 16 and 20 months. The 
latter of these t.wo patients died following retransplantation for liver failure 
secondary to chronic rejection. The other died of recurrent Budd-Chiari 
syndrome when chronic coumadin therapy was discontinued in preparation for 
an elective surgical procedure. 
The two most recently treated patients were women who presented with 
acute thrombosis of both the intrahepatic vena cava and the hepatic veins. 
One also had complete thrombosis of the portal vein, both renal veins and 
both ilio-femoral systems. These patients required extensive thrombectomies 
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during the transplant procedure and both have now survived on chronic anti-
coagulation therapy with no recurrent thromboses. 
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biliary atresia and related disorders 
These disorders account for over 60% of all children who have received 
liver transplants in the cyclosporine era at Pittsburgh and Denver (Figure 8). 
Biliary atresia, per se, is the diagnosis in fully 54% of children, making it the 
single most frequent diagnosis among all patients receiving liver transplanta-
tion in this series. 
Most biliary atresia patients have had a Kasai procedure and many have 
had subsequent attempts at modification of -the original procedure in order to 
obtain drainage of bile. For the most part, a single attempt at a Kasai 
procedure, even with an attempted revision does not pose an increased 
operative risk to the recipient at the time of liver transplantation. On the 
other hand, multiple reoperations for revision of jejunal limbs, creation of 
stomas, and other repeated attempts designed to obtain better drainage may 
seriously complicate removal of the recipient liver. 
Bylers disease, congenital biliary hypoplasia, and Alagille's syndrome are 
other disorders of bile ducts which lead to hepatic failure in childhood and 
require consideration for transplantation. Some of these patients may also 
have had attempts at correction through biliary drainage procedures, usually 
because of some confusion about the true diagnosis. 
One and five year actuarial survival in this group is 76%. Twenty six of 
the total 56 patients are alive one year or more, and twelve two years or more 
following transplantation. The major impediment to adequately treating all 
potential candidates with this disorder, as has been pointed out earlier in this 
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chapter, is the lack of availability of appropriate donors. Biliary atresia and 
related disorders are cured by liver replacement. Many patients who are 
accepted for transplantation die while waiting for a donor to become available. 
metabolic disorders 
Under cyc1osporine therapy, a total of 34 patients with inborn errors of 
metabolism have been treated with liver transplantation, all for cirrhosis 
rather than solely for correction of the metabolic disorder (Table 7). Twenty 
three of the 34 patients were 18 years old or younger at the time of surgery. 
The most common metabolic disorder treated by liver transplantation is 
alpha-I-antitrypsin (A-I-A) deficiency. Patients with Piu phenotype can 
develop macronodular cirrhosis that is sometimes confused with post necrotic 
cirrhosis. Replacement of the liver results in restoration of serum A-I-A 
levels to normal and conversion to Pi.. phenotype.89 Suitability for 
transplantation is somewhat dependent upon the patient's pulmonary status in 
that severe obstructive airway disease may preclude survival following the 
procedure. In general, patients with this disorder are excellent candidates for 
liver replacement. They usually have not had multiple previous abdominal 
procedures. Because transplantation cures the underlying disorder, they are 
generally referred for the procedure soon after they begin to manifest signs 
of significant liver failure, usually before serious physiological deterioration 
and malnutrition have developed. Of the 21 patients with A-I-A, 15 were 
children, 6 adults. The actuarial one and four year survival rate is 67% 
(Figure 9). 
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Wilson's disease is the second most common diagnosis among the 
metabolic disorders. These patients suffer from markedly reduced copper 
excretion and decreased serum ceruloplasmin levels and experience increased 
copper deposition in liver and brain tissue. Medical treatment consists of 
strict adherence to low copper diets, oral potassium sulfide t.o reduce enteral 
absorption of copper and, more recently, the use of D-penici1lamine. Liver re-
placement. corrects t.he disorder of copper metabolism and is indicat.ed when 
hepatic involvement with the disease becomes significant. Patients may 
present for the first time in hepatic failure or in acute hemolytic crisis.90 In 
the authors' series, seven patients have been transplanted with four surviving 
between 6 months and 13 years (Figure 9). In general, waiting for recovery 
from the acute hemolytic crisis and then planning for liver transplantation on 
a semi-elective basis is t.he preferred route to take. 
Hereditary tyrosinemia is another hepatic based disorder of metabolism 
which is corrected by replacement with a normal liver. The accumulation of 
abnormal metabolites of tyrosine which are carcinogenic results in a high 
incidence of malignancies in patients who present with this disorder, although 
the major indication for transplantation is usually cirrhosis.91 All four pa-
tients t.reated for tyrosinemia in t.his series after the introduction of 
cyclosporine are alive from 7 to 37 months following transplantation. 
The t.wo other patients with metabolic disorders include a 17 year old 
girl with Type IV glycogen storage disease and a 41 year old man with 
hemochromatosis. Bot.h are alive at 35 and 12 months respectively. 
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More recently, the authors had an opportunity to treat a 10 year old 
girl with homozygous familial hypercholesterolemia (FH) who had developed 
cardiac failure and intractable angina despite three different attempts at 
coronary artery reconstruction. This patient underwent a combination heart 
and liver transplantation procedure. The patient underwent liver replacement 
solely to correct the underlying disorder, since the native liver was ana-
tomically and otherwise outwardly normal. The procedure appears to have 
been a success since serum cholesterol levels were markedly reduced from 
over 1000 mg/dl prior to transplantation down to less than 300 mg/dl following 
liver transplantation.92 With the continuing improvement in the success rate 
with liver transplantation, the future will undoubtedly see an increasing role 
for the operation in the treatment of not only FH but for a growing list of 
other metabolic disorders which may prove to be hepatic based.93 As an 
example, at Cambridge recently, a young man with severe complications of 
oxalosis was transplanted with no indication other than treatment of the 
metabolic defect. 
alcoholic cirrhosis 
Results of transplantation for patients with cirrhosis secondary to 
alcohol abuse are difficult to assess. Since the introduction of cyclosporine, 
only three patients have been treated and two are dead. Both of these must 
be considered technical failures since they died on the operating table. One 
patient, a 52 year old businessman, is alive and well, leading a productive life 
one year following surgery. Before the advent of cyclosporine, 15 alcoholics 
were transplanted, four of whom lived over one year, three of whom are still 
alive. One patient returned to his former ways following surgery and 56 
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months later was found unconscious in a roadside ditch in Florida, eventually 
dying of pneumonitis. The most difficult issue in deciding to treat these 
patients with liver replacement will continue to be the satisfactory definition 
of reformation from alcoholism. 
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THE RECIPIENT OPERATION 
Although the development of the surgical techniques necessary for the 
successful completion of an orthotopic transplantation of the liver began in 
the laboratory in the late 1950's, the operation in normal dogs often bears 
little resemblance to the operation in a cirrhotic human. The presence of 
severe portal hypertension, particularly in the face of adhesions resulting 
from previous surgical procedures or liver biopsies, can present a markedly 
different kind of challenge. Much of the inherent difficulty of the procedure 
lies in the recipient hepatectomy. Failure to carry off this initial step in 
reasonable safety can jeopardize all of the steps that must follow. 
The recipient operation can be divided into three distinct phases, each 
with its own special problems. The first phase encompasses those steps 
necessary for the removal of the recipient liver. The second phase begins 
after the recipient liver has been removed and the new organ is being sewn 
into place: the so-called anhepatic phase. Restoring blood flow to the new 
liver in the recipient begins the third phase, a phase which also involves the 
sometimes arduous process of obtaining complete hemostasis. 
The Recipient Hepatectomy 
The abdomen is generally opened through bilateral subcostal incisions 
with a vertical extension in the midline toward the xyphoid. Excision of the 
xyphoid provides for greater expansion of the midline wound. Alternatively, a 
Reynolds flap type of incision often provides adequate exposure. A self-
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retaining retractor which attaches to the operating table and can effectively 
spread the rib cage is an indispensable tool for maximizing exposure. 
The recipient operation is begun early enough to allow the surgeon 
sufficient time to exercise meticulous care in removing the diseased liver. 
Liberal use of the electrocautery to make the incision and elsewhere in the 
dissection can help minimize blood loss, but is not a suitable substitute for 
careful surgical technique. Lymphatics and collateral blood vessels in the 
hepatic hilum are ligated and divided to expose the common bile duct, portal 
vein and hepatic arterial supply. The supporting ligaments of the liver can 
be divided with the electrocautery, care being taken to ligate larger blood 
vessels to avoid bleeding later. The retrohepatic vena cava can be freed from 
the diaphragm superiorly down to a point just above the right renal vein. 
Alternatively in adults, if exposure to the hepatic ligaments or the vena cava 
is limited, either because of the extreme size of the liver or because retraction 
of the liver out of the hepatic fossa causes hemodynamic instability, the 
dissection behind the liver can be delayed until after the patient has been 
placed on venous bypass. In this case, hemostasis can be obtained readily 
after the native liver has been removed and before implanting the new liver. 
Bleeding during this initial phase can also be minimized by aggressive 
treatment of pre-existing coagulopathy with blood components. In Pittsburgh, 
the use of the thromboelastograph has allowed the anesthesiologists to 
constantly monitor the status of the patient's coagulation and to react 
accordingly.94 This technique has proven more useful in the operating room 
than repeated measurements of conventional coagulation factors. 
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The Anhepatic Phase 
Once dissection of the liver has been completed and the organ is ready 
to be removed, preparations are made for the anhepatic phase. In the past, 
this has always been the most critical phase, from a physiological standpoint, 
for the recipient. Venous return from the inferior vena cava to the heart is 
completely interrupted. At the same time, both the portal and caval venous 
beds are completely obstructed. Patients tolerate this stage to varying 
degrees. Children in general fare much better than do adults. A venous 
bypass technique which does not require anticoagulation of the recipient was 
developed in the laboratory in Pittsburgh in late 1982 95 and has been used 
routinely in all adults undergoing liver transplantation since February, 1983. 
The details of the technique and the improvements in results attending its 
routine use were the subjects of earlier reports.96 In short, the method of 
venous bypass involves cannulating the divided portal vein and the femoral 
vein through a saphenous vein cut down in order to provide decompression of 
the respective venous beds through a closed system which employs a 
centrifugal force pump to return blood to the superior vena cava by way of 
the axillary vein (see Figure 10). Venous bypass results in the maintenance 
of normal physiology during the anhepatic phase, a virtual elimination of 
intraoperative mortality, a lower incidence of postoperative renal failure or 
gastrointestinal bleeding, and lower blood loss during the transplant operation. 
The technique also markedly reduces the difficulty of those cases wherein 
exposure to retrohepatic structures is impossible or inadequate, by allowing 
one the option of extending the anhepatic phase in order to obtain hemostasis 
in the hepatic fossa after the native liver has been removed. 
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In children, the decision about whether to use bypass can usually be 
made after performing a test clamping of the inflow to the liver and the 
suprahepatic vena cava. Those who experience a marked fall in central 
venous or pulmonary arterial wedge pressure and a resultant decrease in 
cardiac output may require venous bypass. This can be accomplished in most 
children weighing more than 20 kg. without the need for systemic anticoagula-
tion because flow rates in the bypass circuit will be adequate to prevent 
activation of clotting mechanisms. More recently, work has begun in the 
laboratory which no doubt will redefine the acceptable lower limits of flow rate 
so that venous bypass without systemic anticoagulation of the recipient may 
soon be an option for all high risk children undergoing the procedure. 
The native liver is excised by dividing the inflow vessels and the vena 
cava above and below the liver. The upper vena cava and hepatic veins are 
transected as distally as possible in order to maximize length of the upper 
cuff. The septa between these vessels can be cut or one or more of the 
hepatic vein ostia oversewn in order to tailor the diameter of the upper cuff 
to that of the donor upper cava (Figure 11). The lower cava is cut as long 
as possible as well and excess length trimmed to fit the donor organ. 
Once the liver has been removed, some time can be spent obtaining 
hemostasis in the hepatic bed. If bypass is employed, this time is well spent 
because decompression of the caval and portal beds prevents the kind of 
increasing venous congestion that would normally make such attempts futile. 
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The Revascularization and Hemostasis Phase 
The sequencing of I the vascular anastomoses requires careful judgement 
on the part of the operating surgeon. In general, the liver should be 
revascularized within 60 to 75 minutes after it has been removed from cold 
storage and brought up to the recipient. Usually all four anastomoses can be 
accomplished in that period of time so that the liver receives its complete 
blood supply all at once. Normally the upper vena caval anastomosis is 
followed by that of the lower cava. In adults on venous bypass, the arterial 
anastomosis can be done next since the portal vein is decompressed. 
Following that, if clamping the portal vein side of the venous bypass, (in 
order to remove the bypass cannula and perform the portal vein anastomosis), 
results in dimunition of bypass flow to less than 800-1000 mls per minute, the 
arterial inflow to the liver can be restored, the caval clamps removed and the 
patient removed from venous bypass before starting the portal vein 
anastomosis. Most often, however, clamping the portal vein cannula does not 
seriously jeopardize bypass flow. If one anticipates that the arterial 
anastomosis will be particularly difficult or that the inflow from the artery 
may be unreliable, the portal venous anastomosis should be done first. This 
is particularly the case in children or in any patient not benefitting from 
venous bypass. In these instances, the effort should be directed toward 
completing the portal vein anastomosis and releasing the obstructed caval and 
portal systems as rapidly as possible, and then completing the arterial 
anastomosis thereafter. 
Before completing the lower vena caval anastomosis, the donor liver is 
flushed out with cold (4-100 C) lactated Ringers solution through the cannula 
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which was placed into the donor splenic vein during the procurement 
procedure. This precaution washes the preservation solution, high in 
potassium, out of the organ, at the same time evacuating air from the donor 
hepatic veins and vena cava, thus lessening the chance of hperkalemic cardiac 
arrest or massive air embolism at the time that flow is released to the new 
liver. 97 
What usually will prove to be the longest stage of the operation follows 
the revascularization of the new liver. The degree of difficulty in obtaining 
hemostasis at this point is largely dependent upon how successful the team 
has been in controlling the bleeding during the performance of the recipient 
hepatectomy. But following revascularization of the donor liver in the 
recipient, a period of fibrinolysis often occurs. This period can be quite 
short, even clinically unnoticeable, but may sometimes last for several hours if 
it is not anticipated, looked for and effectively treated. The 
thromboelastograph has proven to be particularly useful in this regard. The 
appearance of clot lysis is an indication to use cryoprecipitate and/or 
judicious use of epsilon aminocaproic acid (Amicar). Ultimate control of 
bleeding requires persistence upon the parts of both the surgical team in 
managing so-called surgical bleeding and the anesthesia team in reversing 
coagulopathies. Closing the abdominal incision too early, with the attitude that 
improving hepatic function or some other feat of "Nature" will take care of the 
problem of persistent hemorrhage is a trap which the surgeon should avoid. 
Bile duct reconstruction is delayed until after hemostasis has been 
completed. This allows thorough exposure to all hilar structures while looking 
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for bleeding points and at the same time allows full manipulation and 
retraction of the liver without fear of disrupting the biliary anastomosis. 
biliary reconBtruction 
If the liver recipient has a normal native bile duct, the preferred 
method of reconstruction is a duct to duct anastomosis over a T-tube. With 
this method, the advantage of an intact sphincter of Oddi is preserved. In 
small pediatric patients or in any situation in which either recipient or donor 
bile duct is too small to allow the use of aT-tube, (the smallest normally 
available is # 8 French), a Roux-en-Y loop of jejunum is constructed and a 
choledochojejunostomy performed. In those patients in whom the bile duct is 
diseased (eg. sclerosing cholangitis or biliary atresia and related disorders) or 
damaged (eg. secondary biliary cirrhosis or previous bile duct surgery), a 
Roux-en-Y choledochojejunostomy is the method of reconstruction preferred by 
the authors. The anastomosis is stented with an appropriately sized plastic 
(polyethylene) tube. The authors have had limited experience using the 
method of reconstruction employed by Calne" and have not found the 
technique to offer any advantage over conventional methods of reconstruction. 
At the completion of the biliary anastomosis, a cholangiogram is 
obtained" either through the T-tube, or via a catheter in the cystic duct. 
Routine cholangiography confirms both patency and competency of the duct 
anastomosis and also serves to assure proper positioning of the T-tube or 
stent. 
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Auxiliary or Heterotopic Transplantat.ion 
The possibility of successfully treating some patients with a new liver 
without the need to remove the native organ has remained an intriguing 
possibility. But the world experience, as summarized by Fortner", has been 
rather discouraging, with only one of 50 cases reviewed obtaining unequivocal 
success. Houssin and associates from Paris later reported a second 
success. lOO The major problems have been the frequency of thrombosis of the 
venous outflow and assuring satisfactory portal venous inflow. Optimal revas-
cularization of a liver graft appears to require inflow from the native portal 
system, as demonstrated by previous work.10l.102 
Nevertheless, if a satisfactory technical solution were forthcoming, 
heterotopic transplants would offer the best alternative for patients suffering 
from metabolic disorders with otherwise normal livers, patients with hepatic 
dysfunction of a temporary nature, or in patients at high risk for removal of 
their native liver secondary to a history of extensive surgery in the area or 
from portal vein thrombosis. 
47 
RETRANSPLANTATION 
Until recently, few patients were offered a second transplant for 
treatment of a failing hepatic graft. Figure 12 shows the yearly rate of 
retransplantation and Figure 13 the survival following retransplantation before 
and after the introduction of cyc1osporine. The 19% one year survival rate 
for those given second grafts in the azathioprine era did little to justify its 
increased application. Since 1980, however, survival has begun to exceed 50%, 
and the rate of retransplantation has been between 20 and 25% annually. 
Details of this group of patients given retransplantation were the 
subject of a previous report.S! Rejection of the graft continues to represent 
the most common cause of graft failure leading to retransplantation, with 
technical failures (mostly arterial thromboses), and primary non-function of a 
graft being the other two major categories (Figure 14). Technical failures 
occurred with a frequency that was significantly greater in children than 
adults. 
A total of nine patients in the Pittsburgh series have received three 
liver transplants, five of whom have obtained greater than one year survival. 
As with secondary transplants, timing and the setting under which the 
retransplant occurs are major determinants of ultimate survival. When 
retransplantation is performed in an emergent setting and in the face of 
severe liver failure, the chances of success are much lower than in the more 
elective situation. Likewise, hepatic dysfunction as the result of failure to 
reverse rejection is an indication to consider retransplantation rather than to 
su bject the recipient to the greater risks of increasing immunosuppression. 
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FUTURE PROSPECTS 
Both 1983 and 1984 saw marked improvements in survival rates for liver 
recipients over those for 1982 (Figure 15). Aggressive retransplantation, more 
enlightened use of the new drug, cyclosporine, and the routine use of venous 
bypass for adults are the major reasons for the better results. 
Further improvements could be obtained through better selection of 
patients for the procedure. An· examination of the group of adults 
transplanted using venous bypass revealed· that bypass had a significant 
effect upon 30 day survival in high risk patients, but that these patients 
went through a period of increased mortality thereafter such that their 90 day 
survival was similar to that of those patients transplanted without the use of 
bypass. High risk factors included recurrent episodes of severe 
encephalopathy, massive ascites, severe coagulopathy, recurrent episodes of 
massive gastrointestinal hemorrhage, marked malnutrition and muscle wasting, 
renal failure or a history of multiple previous abdominal surgeries. In a 
another analysis, patients were assigned to one of three groups, solely 
dependent upon their physical location at the time they were called to the 
operating room for the transplant. Six week survival in those who were in 
the intensive care unit was 42% compared to 84% for those in the hospital, but 
on the ward and 68% for those who were called in from home. 
The survival curves in the Pittsburgh series have been obtained without 
any formal process of patient selection. i Better results would follow the 
institution of even the most lenient process of patient selection. In general, 
when assigning priorities to recipients of a service as difficult to obtain in 
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this country (and the world) as liver transplantation, careful consideration 
must be given not just to which patient is the most ill, but also to the 
question of which patient will most likely be benefited by the procedure. 
Suitability for survival of a liver transplant operation is often seriously 
jeopardized by the ravages of advanced hepatic failure. Unlike the field of 
kidney transplantation, transplantation of the liver has had to be developed 
without the benefit of a form of dialysis which would allow for stabilization 
and proper preparation of recipients prior to surgery. The development of an 
effective and practical technique of hepatic dialysis undoubtedly would 
markedly enhance survival for those recipients currently classified as high 
risk for physiologic reasons. 
The increasing participation in the field by a number of new centers 
promises to provide both greater availability of the procedure as a service 
and greater diversity of results. Liver transplantation has become a high 
profile news item, leading some institutions to view the procedure as one 
which might enhance their prestige. Other programs may view a liver 
transplantation service as a means of filling unoccupied hospital beds. But to 
be successful, a liver transplant program requires a tremendous commitment of 
resources, both financial and human. Providing that natural selection rather 
than governmental assignment is allowed to operate, the next few years will 
undoubtedly see the emergence of between fifteen and twenty active centers 
from out of the initial milieu of institutions now starting up programs. 
Major research efforts will center around improving immunosuppression. 
In the near future, a better cyclosporine (cyc}osporin G) which is less 
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nephrotoxic may be forthcoming. In addition, the use of antilymphocyte 
preparations, especially monoclonal antibodies, may prove to be useful 
additions to the armamentarium against rejection. On the other hand, the 
ultimate goal of inducement of donor specific tolerance still appears to be 
beyond the current horizon. 
Developing better methods for liver preservation as well as for 
assessing viability of a liver graft before implantation were mentioned earlier 
as areas in which much research is needed. The future will also see multiple 
organ transplants (such as heart-liver transplants for familial 
hypercholesterolemia or liver-kidney grafts for polycystic disease) receiving 
greater application now that the initial trials with these procedures have be-
gun. 
The field of liver transplantation is in its infancy in terms of the 
potential for development that remains ahead. The first twenty years, largely 
as the result of the unflagging efforts of a few men, saw the technical refine-
ment of one of the most difficult of all surgical procedures to the point that it 
could be taught successfully to other surgeons. The availability, beginning in 
1980, of a new and better immunosuppressant led to better control of what yet 
remains the greatest single source of failure, cell mediated rejection of the 
liver allograft. The future offers physicians involved in the field the 
challenge of making the next chapter one of even greater success in the 
treatment and ultimate prevention of hepatic failure. 
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Table 1: 
Table 2: 
Table 3: 
Table 4: 
Table 5: 
Table 6: 
Table 7: 
Total hospital costs for 31 adults and 55 children undergoing liver 
transplantation in Pittsburgh during fiscal 1983-1984. 
Rehabilitation of liver transplant recipients. 
First clinical trials of orthotopic transplantation of the liver. 
Regimens of immunosuppression developed in kidney transplantation and 
used in liver transplantation. 
Indications for 244 primary liver transplants performed between 
--T~;rarcllqI-f~U-M-dna-griie-PM; 1984. --
-----~-----.. -~~~-------------------
Types of primary tumors in WhiCh patients received liver replacement 
therapy. 
Types of inborn errors of metabolism treated with liver replacement. 
--_ .. _---_.------
Std. 
Dev. 
Medi c.':""I 
Range 
Adults 
All 
n=31 
$ 91,213 
$ 75,691 
... 
$ 45,339 -
$477,766 
TOTAL HOSPITAL COSTS 
FISCAL 1983-84 
Children 
1 graft 
n=44 
$ 60,006 
$ 69,659 
$ 30,937 
$430,956 
Children 
multiple 
n=11 
--------"-
$ 97,321 
$164,762 
$ 93,209 -
$391,753 
[Table 1] 
All 
Children 
n=55 
$82,689 
$75,927 
All 
Patients 
n=86 
$107,931 
$ 85,891 
$ 75,691 
--------
------------ -
REHABILITATION FOLLOWING 
LIVER TRANSPLANTATION 
Pre-cyclosporine Cyclosporine 
~orking--- - 4 34 
= 
~ _____ ----~asewife 6 34 
School 10 4 
Lost job, 5 2 
but able 
Disabled IZI 7 
Totals 25 81 
{Table 2} 
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PRIMARY LIVER TUMORS 
Before Cyclo-
sporine 
Hepatoma 12 (0) 
fibrolamellar 1 (0) 
........ -,-- --IDK=:I:II-I~---:::":;:---D" ---.-- ---
Klatskin's 5 to) 
Cholangio- 1 E~F 
carcinoma 
Sarcomas 2 (1) 
( ) number currently alive over one year 
{Table 6) 
After Cyclo-
sporine 
6 (5) 
~ (4) 
2 (12" 
2 (0) 
3 (1) 
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Figure 1: 
Figure 2: 
Figure 3: 
By permission of the Los Angeles Times Syndicate, 1983. 
Survival of patients given liver transplants in Denver under prednisone 
and azathioprine immunosuppression. by permission of Hepatology (6) 
Survival curves from initial reports of results of liver transplantation 
using cyclosporin-A and prednisone. by permission of Hepatology (6) 
Figure 4: Locations of active liver transplant centers in the United States and 
-~-K- ~-K-- --curope-a:s-oIJuly 19~by permIssion of Transplant Proceedings (7) 
.. 
Figure 5: 
Figure 6: 
Figure 7: 
Figure 8: 
Figure 9: 
Figure 10: 
Figure 11: 
Figure 12: 
Actuarial survival for 244 liver transplants done between March 1, 1980 
and June 30, 1984. 
A comparison of actuarial survival in adults based upon disease 
classification. 
A comparison of actuarial survival of 56 patients transplanted for post-
necrotic cirrhosis based upon age. 
A comparison of actuarial survival in children based upon disease 
classification. 
Actuarial survival for 34 patients transplanted for inborn errors of 
metabolism. 
Anatomy of venous bypass for an hepatic phase of orthotopic liver 
transplantation. 
Development of upper vena caval cuff in recipient. by permission of 
Surgery, Gynecology, and Obstetrics (103) 
Yearly rate of transplantation and retransplantation in Pittsburgh. 
by permission of Transplant Proceedings (81) 
-
Figure 13: 
Figure 14: 
Figure 15: 
A comparison of survival following hepatic retransplantation before and 
after cyclosporine. by permission of Transplant Proceedings (81) 
Indications for hepatic retransplantation under cyclosporine and 
prednisone. by permission of Transplant Proceedings (81) 
Yearly actuarial survival curves since the introduction of cyclosporine. 
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